CN109966308A - 一种犬猫专用肝脏片配方 - Google Patents
一种犬猫专用肝脏片配方 Download PDFInfo
- Publication number
- CN109966308A CN109966308A CN201910397533.0A CN201910397533A CN109966308A CN 109966308 A CN109966308 A CN 109966308A CN 201910397533 A CN201910397533 A CN 201910397533A CN 109966308 A CN109966308 A CN 109966308A
- Authority
- CN
- China
- Prior art keywords
- dog cat
- raw material
- silymarin
- selenium
- methionine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 30
- 241000282326 Felis catus Species 0.000 title claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004471 Glycine Substances 0.000 claims abstract description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 15
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims abstract description 15
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims abstract description 15
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 15
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 15
- 229960002510 mandelic acid Drugs 0.000 claims abstract description 15
- 229930182817 methionine Natural products 0.000 claims abstract description 15
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 15
- 239000011669 selenium Substances 0.000 claims abstract description 15
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims abstract description 15
- 229960004245 silymarin Drugs 0.000 claims abstract description 15
- 235000017700 silymarin Nutrition 0.000 claims abstract description 15
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 229910001385 heavy metal Inorganic materials 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 208000019423 liver disease Diseases 0.000 claims abstract description 7
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 6
- 230000007882 cirrhosis Effects 0.000 claims abstract description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 6
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 6
- 208000006454 hepatitis Diseases 0.000 claims abstract description 6
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 6
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims abstract description 4
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 24
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 14
- 235000013878 L-cysteine Nutrition 0.000 claims description 12
- 239000004201 L-cysteine Substances 0.000 claims description 12
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 238000011287 therapeutic dose Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 231100000572 poisoning Toxicity 0.000 abstract description 2
- 230000000607 poisoning effect Effects 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 1
- QUCGULSUYXHQLW-UHFFFAOYSA-N calcium;2-oxopropanoic acid Chemical compound [Ca].CC(=O)C(O)=O QUCGULSUYXHQLW-UHFFFAOYSA-N 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种犬猫专用肝脏片配方，按照重量计算，包括如下原料：水飞蓟素：25mg‑27mgL‑半胱氨酸：25mg‑27mgL‑谷氨酸：25mg‑27mgL‑甘氨酸：25mg‑27mga‑扁桃酸：5g‑7g蛋氨酸：50g‑52g辅酶Q10:250mg‑252mg丙酮酸钙:125mg‑127mgVB1:3.75g‑5.75gVB2:3.25g‑5.25gVB5:6.25g‑8.25gVB6:3.75g‑5.75gVB12:6.25mg‑8.25mgVF:50mg‑52mgVC:20g‑22gVE:10000IU‑10002IU硒：25mg‑27mg。与其它配方相比，工艺成熟，有效的医治犬猫肝部疾病，适用于犬猫药物性中毒、化学重金属性肝损伤、肝硬化、脂肪肝、肝炎等，对恶性肿瘤引起的肝病有抑制作用，增强犬猫救治的成活率，提高使用效果。
Description
技术领域
本发明涉及犬猫专用肝脏片生产配方技术领域，更具体地说，尤其涉及一种犬猫专用肝脏片配方。
背景技术
犬猫均为我们日常生活中常见的宠物，让我们的生活增添了很多乐趣，有时候会因饲养不当、环境气候等因素引起犬猫的药物性中毒、化学重金属性肝损伤、肝硬化、脂肪肝、肝炎等疾病，恶性肿瘤也会引起肝病产生。
有疾病就需要对其救治，但是现有的犬猫用肝脏片由于配方存在一定的缺陷，降低影响药效，延误最佳的救治时机，严重时导致犬猫的死亡，为此，我们提出一种犬猫专用肝脏片配方。
发明内容
本发明的目的是为了解决现有技术中存在的缺点，而提出的一种犬猫专用肝脏片配方，有效的医治犬猫肝部疾病，适用于犬猫药物性中毒、化学重金属性肝损伤、肝硬化、脂肪肝、肝炎等，对恶性肿瘤引起的肝病有抑制作用，增强犬猫救治的成活率，提高使用效果。
为实现上述目的，本发明提供如下技术方案：一种犬猫专用肝脏片配方，按照重量计算，包括如下原料：
水飞蓟素：25mg-27mg
L-半胱氨酸：25mg-27mg
L-谷氨酸：25mg-27mg
L-甘氨酸：25mg-27mg
a-扁桃酸：5g-7g
蛋氨酸：50g-52g
辅酶Q10:250mg-252mg
丙酮酸钙:125mg-127mg
VB1:3.75g-5.75g
VB2:3.25g-5.25g
VB5:6.25g-8.25g
VB6:3.75g-5.75g
VB12:6.25mg-8.25mg
VF:50mg-52mg
VC:20g-22g
VE:10000IU-10002IU
硒：25mg-27mg。
优选的，按照重量计算，包括如下原料：
水飞蓟素：25mg
L-半胱氨酸：25mg
L-谷氨酸：25mg
L-甘氨酸：25mg
a-扁桃酸：5g
蛋氨酸：50g
辅酶Q10:250mg
丙酮酸钙:125mg
VB1:3.75g
VB2:3.25g
VB5:6.25g
VB6:3.75g
VB12:6.25mg
VF:50mg
VC:20g
VE:10000IU
硒：25mg。
优选的，按照重量计算，包括如下原料：
水飞蓟素：26mg
L-半胱氨酸：26mg
L-谷氨酸：26mg
L-甘氨酸：26mg
a-扁桃酸：6g
蛋氨酸：51g
辅酶Q10:251mg
丙酮酸钙:126mg
VB1:4.75g
VB2:4.25g
VB5:7.25g
VB6:4.75g
VB12:7.25mg
VF:51mg
VC:21g
VE:10001IU
硒：26mg。
优选的，按照重量计算，包括如下原料：
水飞蓟素：27mg
L-半胱氨酸：27mg
L-谷氨酸：27mg
L-甘氨酸：27mg
a-扁桃酸：7g
蛋氨酸：52g
辅酶Q10:252mg
丙酮酸钙:127mg
VB1:5.75g
VB2:5.25g
VB5:8.25g
VB6:5.75g
VB12:8.25mg
VF:52mg
VC:22g
VE:10002IU
硒：27mg。
优选的，制作方法包括如下步骤：
S1、称取物料：根据权利要求2或权利要求3或权利要求4其中的任意一组数据，称取原材料水飞蓟素、L-半胱氨酸、L-谷氨酸、L-甘氨酸、a-扁桃酸、蛋氨酸、辅酶Q10、丙酮酸钙、VB1、VB2、VB5、VB6、VB12、VF、VC、VE和硒；
S2、搅拌混合：把称取之后的原材料依次倒进容器内，通过搅拌机搅拌使原材料充分混合，搅拌时间不低于两小时；
S3、挤压成型：把充分混合的原料放入成型块内部，通过挤压把原料制成片状；
S4、抽样检测：每批次药片从五十片里随机抽取三片，对单个药片进行溶解，检测其药物含量的成分，取三片药片的平均值，与标准值比对，判断每批次药片是否符合标准；
S5、密封保存：把符合药物标准的药片，放入密封袋里，放在干燥通风储存。
优选的，用法与用量：适用于药物性中毒、化学重金属性肝损伤、肝硬化、脂肪肝、肝炎等，对恶性肿瘤引起的肝病有抑制作用,治疗量每10kg服用2片，维持量每10kg服用一片,病情严重者酌情加量。
本发明的技术效果和优点：
1、保护肝细胞免受毒性物质的侵害(如：医源性药物治疗的长期使用，重金属、化学性物质等)，尤其是对药物性中毒效果显著。对损伤的肝细胞有保护作用！
2、降低肝细胞的衰老速度，延长肝细胞的生物活性、促进蛋白质的合成、加快肝细胞的生成与再修复。
3、抗癌、抗放射性——降低恶性肿瘤引起的白细胞减少症。可在体内与有毒化合物或致癌物质相结合，促使其排出体外。
4、含有较强的抗氧化物质，能有效的减少自由基的生成，保护肝细胞免受损伤。机体内抗氧化成分越强，肝细胞的生成与再修复就越稳定。
5、为肝脏功能恢复提供所需的氨基酸、维他命以及矿物质。
6、提高机体的免疫系统，增强肝脏的解毒功能。
7、促进脂肪的排出(以磷脂的形式在肝脏通过血液输送出去)，降低脂肪在肝内的利用度。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合具体实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
一种犬猫专用肝脏片配方，包括如下步骤：按照重量计算，包括如下原料：
水飞蓟素：25mg-27mg
L-半胱氨酸：25mg-27mg
L-谷氨酸：25mg-27mg
L-甘氨酸：25mg-27mg
a-扁桃酸：5g-7g
蛋氨酸：50g-52g
辅酶Q10:250mg-252mg
丙酮酸钙:125mg-127mg
VB1:3.75g-5.75g
VB2:3.25g-5.25g
VB5:6.25g-8.25g
VB6:3.75g-5.75g
VB12:6.25mg-8.25mg
VF:50mg-52mg
VC:20g-22g
VE:10000IU-10002IU
硒：25mg-27mg。
实施例2
一种犬猫专用肝脏片配方，包括如下步骤：按照重量计算，包括如下原料：
水飞蓟素：25mg
L-半胱氨酸：25mg
L-谷氨酸：25mg
L-甘氨酸：25mg
a-扁桃酸：5g
蛋氨酸：50g
辅酶Q10:250mg
丙酮酸钙:125mg
VB1:3.75g
VB2:3.25g
VB5:6.25g
VB6:3.75g
VB12:6.25mg
VF:50mg
VC:20g
VE:10000IU
硒：25mg。
实施例3
一种犬猫专用肝脏片配方，包括如下步骤：按照重量计算，包括如下原料：
水飞蓟素：26mg
L-半胱氨酸：26mg
L-谷氨酸：26mg
L-甘氨酸：26mg
a-扁桃酸：6g
蛋氨酸：51g
辅酶Q10:251mg
丙酮酸钙:126mg
VB1:4.75g
VB2:4.25g
VB5:7.25g
VB6:4.75g
VB12:7.25mg
VF:51mg
VC:21g
VE:10001IU
硒：26mg。
实施例4
一种犬猫专用肝脏片配方，包括如下步骤：按照重量计算，包括如下原料：
水飞蓟素：27mg
L-半胱氨酸：27mg
L-谷氨酸：27mg
L-甘氨酸：27mg
a-扁桃酸：7g
蛋氨酸：52g
辅酶Q10:252mg
丙酮酸钙:127mg
VB1:5.75g
VB2:5.25g
VB5:8.25g
VB6:5.75g
VB12:8.25mg
VF:52mg
VC:22g
VE:10002IU
硒：27mg。
综上所述：本发明提供的一种犬猫专用肝脏片配方，与其它配方相比，工艺成熟，适用于药物性中毒、化学重金属性肝损伤、肝硬化、脂肪肝、肝炎等，对恶性肿瘤引起的肝病有抑制作用。保护肝细胞免受毒性物质的侵害(如：医源性药物治疗的长期使用，重金属、化学性物质等)，尤其是对药物性中毒效果显著。对损伤的肝细胞有保护作用！降低肝细胞的衰老速度，延长肝细胞的生物活性、促进蛋白质的合成、加快肝细胞的生成与再修复。抗癌、抗放射性——降低恶性肿瘤引起的白细胞减少症。可在体内与有毒化合物或致癌物质相结合，促使其排出体外。含有较强的抗氧化物质，能有效的减少自由基的生成，保护肝细胞免受损伤。机体内抗氧化成分越强，肝细胞的生成与再修复就越稳定。为肝脏功能恢复提供所需的氨基酸、维他命以及矿物质。提高机体的免疫系统，增强肝脏的解毒功能。促进脂肪的排出(以磷脂的形式在肝脏通过血液输送出去)，降低脂肪在肝内的利用度。
最后应说明的是：以上所述仅为本发明的优选实施例而已，并不用于限制本发明，尽管参照前述实施例对本发明进行了详细的说明，对于本领域的技术人员来说，其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (6)
1.一种犬猫专用肝脏片配方，其特征在于：按照重量计算，包括如下原料：
水飞蓟素：25mg-27mg
L-半胱氨酸：25mg-27mg
L-谷氨酸：25mg-27mg
L-甘氨酸：25mg-27mg
a-扁桃酸：5g-7g
蛋氨酸：50g-52g
辅酶Q10:250mg-252mg
丙酮酸钙:125mg-127mg
VB1:3.75g-5.75g
VB2:3.25g-5.25g
VB5:6.25g-8.25g
VB6:3.75g-5.75g
VB12:6.25mg-8.25mg
VF:50mg-52mg
VC:20g-22g
VE:10000IU-10002IU
硒：25mg-27mg。
2.根据权利要求1所述的一种犬猫专用肝脏片配方，其特征在于：按照重量计算，包括如下原料：
水飞蓟素：25mg
L-半胱氨酸：25mg
L-谷氨酸：25mg
L-甘氨酸：25mg
a-扁桃酸：5g
蛋氨酸：50g
辅酶Q10:250mg
丙酮酸钙:125mg
VB1:3.75g
VB2:3.25g
VB5:6.25g
VB6:3.75g
VB12:6.25mg
VF:50mg
VC:20g
VE:10000IU
硒：25mg。
3.根据权利要求1所述的一种犬猫专用肝脏片配方，其特征在于：按照重量计算，包括如下原料：
水飞蓟素：26mg
L-半胱氨酸：26mg
L-谷氨酸：26mg
L-甘氨酸：26mg
a-扁桃酸：6g
蛋氨酸：51g
辅酶Q10:251mg
丙酮酸钙:126mg
VB1:4.75g
VB2:4.25g
VB5:7.25g
VB6:4.75g
VB12:7.25mg
VF:51mg
VC:21g
VE:10001IU
硒：26mg。
4.根据权利要求1所述的一种犬猫专用肝脏片配方，其特征在于：按照重量计算，包括如下原料：
水飞蓟素：27mg
L-半胱氨酸：27mg
L-谷氨酸：27mg
L-甘氨酸：27mg
a-扁桃酸：7g
蛋氨酸：52g
辅酶Q10:252mg
丙酮酸钙:127mg
VB1:5.75g
VB2:5.25g
VB5:8.25g
VB6:5.75g
VB12:8.25mg
VF:52mg
VC:22g
VE:10002IU
硒：27mg。
5.根据权利要求1所述的一种犬猫专用肝脏片配方，其特征在于：制作方法包括如下步骤：
S1、称取物料：根据权利要求2或权利要求3或权利要求4其中的任意一组数据，称取原材料水飞蓟素、L-半胱氨酸、L-谷氨酸、L-甘氨酸、a-扁桃酸、蛋氨酸、辅酶Q10、丙酮酸钙、VB1、VB2、VB5、VB6、VB12、VF、VC、VE和硒；
S2、搅拌混合：把称取之后的原材料依次倒进容器内，通过搅拌机搅拌使原材料充分混合，搅拌时间不低于两小时；
S3、挤压成型：把充分混合的原料放入成型块内部，通过挤压把原料制成片状；
S4、抽样检测：每批次药片从五十片里随机抽取三片，对单个药片进行溶解，检测其药物含量的成分，取三片药片的平均值，与标准值比对，判断每批次药片是否符合标准；
S5、密封保存：把符合药物标准的药片，放入密封袋里，放在干燥通风储存。
6.根据权利要求1所述的一种犬猫专用肝脏片配方，其特征在于：用法与用量：适用于药物性中毒、化学重金属性肝损伤、肝硬化、脂肪肝、肝炎等，对恶性肿瘤引起的肝病有抑制作用,治疗量每10kg服用2片，维持量每10kg服用一片,病情严重者酌情加量。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910397533.0A CN109966308A (zh) | 2019-05-14 | 2019-05-14 | 一种犬猫专用肝脏片配方 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910397533.0A CN109966308A (zh) | 2019-05-14 | 2019-05-14 | 一种犬猫专用肝脏片配方 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109966308A true CN109966308A (zh) | 2019-07-05 |
Family
ID=67073655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910397533.0A Pending CN109966308A (zh) | 2019-05-14 | 2019-05-14 | 一种犬猫专用肝脏片配方 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109966308A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030091552A1 (en) * | 2001-11-13 | 2003-05-15 | Rudolph Cartwright | Nutraceutical composition |
| CN1739767A (zh) * | 2005-09-06 | 2006-03-01 | 易康富生物科技(南通)有限公司 | 一种能保肝护肝和改善肝病症状的复合配方 |
| CN101019888A (zh) * | 2006-12-28 | 2007-08-22 | 银小龙 | 治疗脂肪肝、酒精肝,降血脂、降转氨酶的药物 |
| CN103181940A (zh) * | 2011-12-31 | 2013-07-03 | 瑞普（天津）生物药业有限公司 | 一种宠物用保肝营养美味片 |
| CN107184598A (zh) * | 2017-04-28 | 2017-09-22 | 深圳市众康动保科技有限公司 | 一种宠物用心脏病复方片剂 |
| CN108014324A (zh) * | 2017-10-24 | 2018-05-11 | 中国科学院兰州化学物理研究所 | 一种具有保护酒精性肝损伤功效的保健制剂 |
-
2019
- 2019-05-14 CN CN201910397533.0A patent/CN109966308A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030091552A1 (en) * | 2001-11-13 | 2003-05-15 | Rudolph Cartwright | Nutraceutical composition |
| CN1739767A (zh) * | 2005-09-06 | 2006-03-01 | 易康富生物科技(南通)有限公司 | 一种能保肝护肝和改善肝病症状的复合配方 |
| CN101019888A (zh) * | 2006-12-28 | 2007-08-22 | 银小龙 | 治疗脂肪肝、酒精肝,降血脂、降转氨酶的药物 |
| CN103181940A (zh) * | 2011-12-31 | 2013-07-03 | 瑞普（天津）生物药业有限公司 | 一种宠物用保肝营养美味片 |
| CN107184598A (zh) * | 2017-04-28 | 2017-09-22 | 深圳市众康动保科技有限公司 | 一种宠物用心脏病复方片剂 |
| CN108014324A (zh) * | 2017-10-24 | 2018-05-11 | 中国科学院兰州化学物理研究所 | 一种具有保护酒精性肝损伤功效的保健制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5554069B2 (ja) | ビタミンおよびミネラル補助食品における改善された安定性 | |
| JP4653400B2 (ja) | 糖尿病用組成物 | |
| CN106727481B (zh) | 绿原酸在制备增强食欲的药物或保健品中的用途 | |
| JP4447913B2 (ja) | オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用 | |
| IE48842B1 (en) | Medicated animal feed based on liver meal and process for preparing it | |
| TW201408299A (zh) | 不含鹼化劑之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）調配物 | |
| JP2007125019A (ja) | 精液の生産増加方法およびその質の改良方法 | |
| CN111295102A (zh) | 氨基酸补充剂在提高肌肉蛋白质合成中的用途 | |
| JPWO2014038630A1 (ja) | セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品 | |
| CN109966308A (zh) | 一种犬猫专用肝脏片配方 | |
| CN106349318B (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
| US20230227456A1 (en) | Oral formulation comprising a crystalline form of rabeximod | |
| CN113143962B (zh) | 一种治疗高脂血症的药物组合物及其制备方法 | |
| JP3604710B2 (ja) | 骨粗鬆症予防及び治療剤 | |
| JPH07118148A (ja) | 肝癌予防剤 | |
| JP2022143483A (ja) | 経口組成物、筋肉増強用組成物並びに抗肥満用組成物 | |
| DE202012104963U1 (de) | Cetilistat aufweisende Zusammensetzungen | |
| JP2018519322A (ja) | 海洋ペプチドおよび筋肉の健康 | |
| CN112957409A (zh) | 一种葡萄籽红花籽油组合物及其应用 | |
| CN106806382B (zh) | 抗癌组合物 | |
| CN106690123A (zh) | 一种海蜇制品及海蜇在制备促进人体排铝的产品中的应用 | |
| EP2535047A1 (en) | Nutritional composition, food supplement comprising said nutritional composition and kit comprising said food supplement | |
| KR102679687B1 (ko) | 비-알코올성 지방간염 비-인간 동물모델의 제조를 위한 조성물 및 이의 용도 | |
| JP6641626B2 (ja) | 制酸用医薬組成物 | |
| US20220079975A1 (en) | Method for mitigation of non-alcoholic fatty liver disease by use of a composition comprising small-molecule fucoidan and fucoxanthin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |
|
| RJ01 | Rejection of invention patent application after publication |